Leflunomide

E-ISSN： 2047-2900|35|1|34-35

ISSN： 2047-2897

Source： PRACTICAL DIABETES (INCORPORATING CARDIABETES), Vol.35, Iss.1, 2018-01, pp. : 34-35

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Valsartan for progressive IgA nephropathy

NEPHROLOGY, Vol. 20, Iss. 2, 2015-02 ,pp. : 77-84

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inhibition of Cytomegalovirus in vitro and in vivo by the Experimental Immunosuppressive Agent Leflunomide

Intervirology, Vol. 42, Iss. 5-6, 2000-02 ,pp. : 412-418

Karger

Access to resources Recommend Favorite

A 771726, the Active Metabolite of Leflunomide, Inhibits TNF-α and IL-1 from Kupffer Cells

By Yao Hong Wei Li Jun Chen Ji Qiang Xu Shu Yun

Inflammation, Vol. 28, Iss. 2, 2004-04 ,pp. : 97-103

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety of leflunomide in DMARD-nave patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen

By Cutolo Maurizio

British Journal of Rheumatology , Vol. 52, Iss. 6, 2013-06 ,pp. : 1132-1140

Oxford University Press

Access to resources Recommend Favorite

Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 20, Iss. 11, 2017-11 ,pp. : 1795-1797

John Wiley & Sons Inc

Access to resources Recommend Favorite